Equities

Hisamitsu Pharmaceutical Co Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Hisamitsu Pharmaceutical Co Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)6,190.00
  • Today's Change0.00 / 0.00%
  • Shares traded350.70k
  • 1 Year change+42.96%
  • Beta0.6196
Data delayed at least 15 minutes, as of Feb 16 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.

  • Revenue in JPY (TTM)159.27bn
  • Net income in JPY19.99bn
  • Incorporated1944
  • Employees2.80k
  • Location
    Hisamitsu Pharmaceutical Co Inc30F, Marunouchi Bldg., 2-4-1, MarunouchiCHIYODA-KU 100-6330JapanJPN
  • Phone+81 352931700
  • Fax+81 352931750
  • Websitehttps://www.hisamitsu.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kyorin Pharmaceutical Co Ltd133.26bn10.77bn99.87bn2.00k8.890.68926.490.7495187.40187.402,319.592,417.370.69271.082.9366,695,200.005.603.347.034.1645.3245.898.085.112.05--0.174657.348.833.4170.738.1214.36-7.06
Katakura Industries Co Ltd40.98bn5.84bn106.53bn941.0016.591.0612.112.60182.30182.301,278.512,853.060.29262.156.4243,545,160.004.272.605.203.5736.1637.9814.599.442.63--0.080723.42-1.37-2.1915.7315.27-7.2233.03
Zeria Pharmaceutical Co Ltd86.61bn7.26bn113.33bn1.75k13.451.027.791.31164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Mochida Pharmaceutical Co Ltd111.92bn6.42bn135.73bn1.51k20.590.962114.461.21181.16181.163,156.953,876.770.64271.673.0274,214,190.003.694.504.475.4448.4352.495.746.872.85--0.067843.012.210.651625.034.341.980.00
Kaken Pharmaceutical Co Ltd75.66bn-3.83bn186.49bn1.13k--1.10--2.46-97.11-97.111,980.563,850.390.40911.862.8067,195,380.00-2.075.99-2.426.8753.0956.17-5.0612.913.21--0.025759.5830.521.0573.77-6.3614.810.00
Towa Pharmaceutical Co Ltd269.92bn21.44bn191.64bn4.79k8.540.96544.400.71435.61435.615,483.173,853.290.56951.493.3756,374,690.004.523.895.535.0736.7237.817.946.611.5432.770.551921.5213.8918.6517.395.5346.239.73
Kissei Pharmaceutical Co Ltd95.29bn14.14bn216.42bn1.78k13.780.890811.462.27337.47337.472,274.295,220.290.37481.852.8353,596,180.005.624.266.194.6048.2148.5914.9914.303.42--0.005832.4116.876.917.1833.5431.0413.97
Sawai Group Holdings Co Ltd200.68bn-1.25bn264.52bn3.31k--1.4818.311.32-9.86-22.641,734.071,548.250.54451.283.4060,628,400.00-0.3389-0.2327-0.4542-0.318728.8932.95-0.6224-0.4751.08-1.040.4066191.656.880.7009-87.38-35.388.654.11
Tsumura & Co189.50bn29.01bn310.79bn4.27k10.460.98857.291.64387.15387.152,524.844,095.990.3740.71062.4144,357,680.006.015.538.066.8547.6049.3916.0614.501.45--0.285631.6520.058.0094.1018.6923.0716.27
Nippon Shinyaku Co Ltd166.05bn29.85bn349.71bn2.24k11.231.189.662.11443.17443.172,465.264,211.800.54211.173.1974,028,980.009.7510.8910.8112.7467.2963.9317.9817.674.04--0.008930.588.086.5625.9414.0680.487.59
Hisamitsu Pharmaceutical Co Inc159.27bn19.99bn465.27bn2.80k22.351.6116.902.92276.99276.992,208.133,837.320.47042.643.4256,901,390.006.044.347.254.9959.0557.8312.8410.323.28--0.008650.2910.092.0455.763.0829.890.7127
Santen Pharmaceutical Co Ltd287.99bn30.60bn554.31bn3.85k18.691.9511.381.9292.0392.03865.27880.970.72052.264.1874,823,070.007.633.949.434.9356.8958.9710.596.011.89--0.175771.86-0.64944.4336.098.943.615.92
Rohto Pharmaceutical Co Ltd335.80bn34.48bn593.75bn9.14k16.951.9811.411.77148.28148.281,444.671,272.140.77682.324.5536,723,640.008.028.5911.2011.7056.0657.7810.3310.571.43--0.145221.1213.9510.380.226315.0110.4222.59
Data as of Feb 16 2026. Currency figures normalised to Hisamitsu Pharmaceutical Co Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

10.65%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 20262.00m2.66%
Nomura Asset Management Co., Ltd.as of 05 Feb 20261.39m1.84%
Norges Bank Investment Managementas of 30 Jun 20251.17m1.56%
BlackRock Fund Advisorsas of 06 Feb 2026715.80k0.95%
Amova Asset Management Co., Ltd.as of 06 Feb 2026681.40k0.91%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026619.70k0.82%
Goldman Sachs Asset Management LPas of 31 Oct 2025587.30k0.78%
Dimensional Fund Advisors LPas of 31 Jan 2026372.30k0.50%
Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024277.90k0.37%
Charles Schwab Investment Management, Inc.as of 05 Feb 2026196.70k0.26%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.